Status:
COMPLETED
A Study of Single-Dose Gabapentin in Subjects With Transient Insomnia Induced by a Sleep Phase Advance
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Transient Insomnia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the effect of gabapentin as compared to placebo on sleep, using subjective sleep measurements, in subjects with transient insomnia induced by a sleep phase advan...
Eligibility Criteria
Inclusion
- Aged \>/= 18 years
- Females of child-bearing potential using medically-acceptable method of birth control \>/= 1 month prior to screening
Exclusion
- Current or recent history (within 2 years) of sleep disorder (excessive snoring, obstructive sleep apnea, chronic painful condition)
- Recreational drug use within past 30 days
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2005
Estimated Enrollment :
773 Patients enrolled
Trial Details
Trial ID
NCT00666939
Start Date
October 1 2004
End Date
January 1 2005
Last Update
February 2 2021
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
San Diego, California, United States, 92108
2
Pfizer Investigational Site
Ocala, Florida, United States, 34471
3
Pfizer Investigational Site
Atlanta, Georgia, United States, 30328
4
Pfizer Investigational Site
Atlanta, Georgia, United States, 30342